In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

With $30 Million Series B In Hand, Elevation Prepares To Take Inhalable COPD Drug Up To Phase III

This article was originally published in The Pink Sheet Daily

Executive Summary

The two-tranche financing, backed 50% by new investor Novo Ventures, will enable the private firm to evaluate early partnering opportunities from a position of financial stability.

You may also be interested in...



Sunovion To Purchase Elevation And Phase II Drug/Device Combo For COPD

Earlier than anticipated exit for Elevation means less dilution for its venture capital backers, who had provided $30 million in Series B funds this past January.

Deals Of The Week: Sunovion/Elevation, Janssen/Genmab, Alnylam/Monsanto

With Roche’s Pascal Soriot set to become AstraZeneca’s CEO on Oct. 1, Soriot’s success in merging Genentech into Roche may open up AZ’s business development strategy to large-scale M&A.

Sunovion To Purchase Elevation And Phase II Drug/Device Combo For COPD

Earlier than anticipated exit for Elevation means less dilution for its venture capital backers, who had provided $30 million in Series B funds this past January.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS073218

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel